Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the stock. TD Cowen upgraded shares of Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Bank of America lowered their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.60.

Sana Biotechnology Trading Up 1.3%

Shares of SANA opened at $2.37 on Friday. The stock has a 50-day moving average price of $2.88 and a 200-day moving average price of $3.35. Sana Biotechnology has a 12-month low of $2.22 and a 12-month high of $5.49. The company has a market cap of $709.48 million, a PE ratio of -4.47 and a beta of 2.30.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, analysts predict that Sana Biotechnology will post -0.72 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

Several hedge funds have recently modified their holdings of SANA. Walleye Capital LLC acquired a new stake in shares of Sana Biotechnology during the 2nd quarter valued at $35,000. Royal Bank of Canada raised its position in shares of Sana Biotechnology by 76.8% during the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after purchasing an additional 5,338 shares during the period. Abel Hall LLC purchased a new position in Sana Biotechnology in the third quarter worth $35,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after buying an additional 4,088 shares during the period. Finally, Callan Family Office LLC purchased a new stake in shares of Sana Biotechnology in the second quarter valued at $43,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.